Prepare to transform your understanding of cancer. Dr. Noah Gudel, with over 13 years of experience in lifestyle medicine, will share her insights on the metabolic aspects of cancer. Learn how addressing the root causes, rather than just the symptoms, can lead to more effective treatments and overall health improvement. Dr. Gudel’s approach, enriched by her personal journey and professional expertise, promises to offer practical tips for everyday wellness. This is an opportunity to gain invaluable knowledge from an expert who combines medical practice with a holistic lifestyle approach.

Read about this class:

For years, cancer has been understood primarily as a genetic disease, an accumulation of DNA damage that drives malignancy. However, Dr. Noah Gude presents a compelling argument that cancer is, in fact, a metabolic disease—a shift that could have profound implications for prevention, diagnosis, and treatment.

The Flawed Genetic Model

In medical education, it is assumed that cancer results from genetic mutations. This belief is so ingrained that it is never questioned, much like the fact that the sky is blue. However, research reveals contradictions in this theory:

• Tumor genetic variability: Cells within the same tumor often have different genetic mutations, making targeted gene therapy an imprecise approach.
• Mutations without cancer: Many people carry mutations associated with cancer yet never develop the disease.
• Low gene mutation rates: The natural rate of genetic mutation is too low to account for the frequency and rapid onset of many cancers.
• Caretaker gene instability: Essential protective genes, such as p53 and BRCA1, are paradoxically fragile—raising the question of how humans could have evolved if these genes were so easily damaged.

The Ineffectiveness of Chemotherapy

Despite its widespread use, chemotherapy has shown shockingly low success rates in adult cancers:

• A 2004 study found that chemotherapy contributed to five-year survival in adult malignancies only 2.1% of the time.
• Certain cancers, such as pancreatic and renal cell carcinoma, show no benefit from chemotherapy.
• Some exceptions exist, such as Hodgkin’s lymphoma and childhood cancers, where chemotherapy is more effective.

The focus of cancer research remains fixated on genetics, largely because of industry and academic incentives. Pharmaceutical companies profit from expensive gene-targeted therapies, despite their limited success. Meanwhile, academic careers depend on publishing studies, which often favor trending topics like genetics rather than exploring cancer’s root causes.

The Problem with Cancer Research Models

Cancer studies often rely on mice, but this presents major issues:

• Metabolic differences: Mice have a metabolic rate seven times higher than humans, making results difficult to translate.
• Immune system deficiencies: The most commonly used cancer research mice, NOD-SCID mice, lack a normal immune system, creating an unrealistic testing environment.
• Misleading results: Studies frequently tout promising treatments based on cell culture experiments, but these results often fail in real-world applications.

The Forgotten Metabolic Theory of Cancer

Over a century ago, Otto Warburg proposed that cancer is a metabolic disease driven by damaged mitochondrial function. His work was largely ignored, but his findings remain relevant today:

• Cancer cells rely on inefficient energy production: Unlike healthy cells that generate energy in the mitochondria (36 ATP per glucose molecule), cancer cells ferment glucose in the cytoplasm, producing only 2 ATP per glucose.
• PET scans detect cancer using glucose: The fact that cancer thrives on sugar is so well established that PET scans use radiolabeled glucose to locate tumors.
• Mitochondrial damage is universal in cancer: No known cancer cells exhibit completely normal mitochondrial function.

What Causes Mitochondrial Damage?

Many environmental and lifestyle factors contribute to mitochondrial dysfunction, including:

• Viruses: Hepatitis C, Epstein-Barr, and HPV have been linked to cancer.
• Radiation: While used as a treatment, radiation itself damages mitochondria and increases inflammation.
• Diet: Highly processed foods, sugar, and inflammatory diets contribute to cancer risk.
• Obesity: Fat tissue is metabolically active, producing inflammation and converting estrogen to its active form, increasing cancer risk.
• Medical interventions: Chemotherapy and radiation, while intended to treat cancer, also cause necrosis and chronic inflammation, further driving disease progression.

The Role of Chronic Inflammation

Inflammation plays a central role in cancer development. As early as 1863, Rudolf Virchow described cancer as a "wound that does not heal," recognizing its link to chronic inflammation. This connection is now well understood:

• Necrotic cell death fuels cancer: Unlike normal programmed cell death (apoptosis), necrosis triggers inflammation, which encourages tumor growth.
• Modern lifestyle factors: Poor diet, obesity, and environmental toxins all contribute to chronic inflammation, increasing cancer risk.
• Misguided treatments: Some commonly used medications, such as statins, have been shown to cause mitochondrial damage, potentially increasing cancer risk.

A New Approach to Cancer Treatment

If cancer is a metabolic disease, treatment should shift away from ineffective genetic-targeting drugs and toward therapies that support mitochondrial function and reduce inflammation. Potential strategies include:

• Dietary changes: Reducing sugar intake and focusing on whole, anti-inflammatory foods.
• Metabolic therapies: Emerging research supports approaches like the ketogenic diet, fasting, and hyperbaric oxygen therapy.
• Addressing root causes: Reducing exposure to environmental toxins, chronic infections, and radiation.

The Urgent Need for Change

Despite overwhelming evidence, mainstream medicine continues to treat cancer as a genetic disease, ignoring metabolic factors that could lead to better prevention and treatment. Medical education, research funding, and industry incentives all play a role in maintaining the status quo. However, understanding cancer as a metabolic disease offers a new, more promising direction for fighting this devastating illness.